Voruciclib

Voruciclib

Voruciclib is an orally active, selective cyclin-dependent kinase (CDK) inhibitor. It effectively inhibits CDK9, a key regulator of MCL-1 transcription. In various diffuse large B-cell lymphoma (DLBCL) models, Voruciclib suppresses MCL-1 expression. This compound is significant in PROTAC development due to its ability to selectively inhibit CDKs and modulate transcriptional regulation. Reagent grade, for research purpose.

Molecular structure of the compound BP-40078
    • Unit
    • Price
    • Qty
    • 5 MG
    • $430.00
    • 10 MG
    • $680.00

Usually ships within 24 hours.

Would you like to inquire about custom quantity?
Inquire